Huya Bioscience Enters Into U.S., European Deals That Could Help Channel Innovative Chinese Drugs Into Pipelines Of International Pharma Outfits

BEIJING - In transactions that could help channel innovative Chinese drugs into the pipelines of global pharmaceutical outfits, Huya Bioscience International has signed separate deals with the U.S.-headquartered Abbott Laboratories and the Belgian-based Solvay Pharmaceuticals to identify lead compounds for potential licensing agreements